

## Cyclophos - (500 mg/2.5 mL and 1 g/5 mL ; Solution, Intravenous)

|                              |                                                                                                                                                                                                                                                                                                                                                   |                             |                     |
|------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|---------------------|
| <b>Generic Name</b>          | Cyclophosphamide                                                                                                                                                                                                                                                                                                                                  | <b>Innovator</b>            | Ingenus pharma      |
| <b>Dosage</b>                | 500 mg/2.5 mL and 1 g/5 mL ; Solution, Intravenous                                                                                                                                                                                                                                                                                                | <b>Branded US Sales</b>     | Less Than \$1000 mn |
| <b>Probable FTF</b>          | Less Than 5                                                                                                                                                                                                                                                                                                                                       | <b>Known Para IV Filers</b> | Less Than 5         |
| <b>Other ANDA developers</b> | Less Than 5                                                                                                                                                                                                                                                                                                                                       | <b>Tentative Approvals</b>  | Less Than 5         |
| <b>Final Approvals</b>       | Less Than 5                                                                                                                                                                                                                                                                                                                                       | <b>Generic Launches</b>     | None                |
| <b>Indication</b>            | Cyclophosphamide is an alkylating drug indicated for treatment of Malignant Diseases: malignant lymphomas: Hodgkin's disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt's lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma. |                             |                     |
| <b>Complexities</b>          | Yes                                                                                                                                                                                                                                                                                                                                               |                             |                     |

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

## Cyclophos - (2 g/10 mL; Solution, Intravenous)

|                              |                                                                                                                                                                                                                                                                                                                                                    |                             |                     |
|------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|---------------------|
| <b>Generic Name</b>          | Cyclophosphamide                                                                                                                                                                                                                                                                                                                                   | <b>Innovator</b>            | Ingenus pharma      |
| <b>Dosage</b>                | 2 g/10 mL; Solution, Intravenous                                                                                                                                                                                                                                                                                                                   | <b>Branded US Sales</b>     | Less Than \$1000 mn |
| <b>Probable FTF</b>          | Less Than 5                                                                                                                                                                                                                                                                                                                                        | <b>Known Para IV Filers</b> | Less Than 5         |
| <b>Other ANDA developers</b> | Less Than 5                                                                                                                                                                                                                                                                                                                                        | <b>Tentative Approvals</b>  | Less Than 5         |
| <b>Final Approvals</b>       | None                                                                                                                                                                                                                                                                                                                                               | <b>Generic Launches</b>     | None                |
| <b>Indication</b>            | Cyclophosphamide is an alkylating drug indicated for treatment of Malignant Diseases (malignant lymphomas: Hodgkin's disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt's lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma). |                             |                     |
| <b>Complexities</b>          | Yes                                                                                                                                                                                                                                                                                                                                                |                             |                     |

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.